A multicentre open-label phase IIa study with escalating dose of MS1819-SD, to investigate the efficacy and safety of a Yarrowia lipolytica lipase preparation for the compensation of exocrine pancreatic insufficiency caused by chronic pancreatitis and/or distal pancreatectomy.
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Lipase (Primary)
- Indications Exocrine pancreatic insufficiency; Pancreatitis
- Focus Adverse reactions
- Acronyms MS1819-SD
- 11 Apr 2017 AzurRx continues to expect completion of this Phase IIa trial in 3Q17, according to a company media release.
- 11 Apr 2017 Early results published in the an AzurRx BioPharma media release.
- 21 Dec 2016 According to an AzurRx BioPharma media relase, first three patients have been enrolled in this trial.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History